These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 7927834)

  • 1. Mechanisms of quinolone resistance.
    Wiedemann B; Heisig P
    Infection; 1994; 22 Suppl 2():S73-9. PubMed ID: 7927834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of resistance to quinolones.
    Cambau E; Gutmann L
    Drugs; 1993; 45 Suppl 3():15-23. PubMed ID: 7689446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Causes of quinolone resistance in gram-negative bacteria].
    Cullmann W
    Immun Infekt; 1990 Jun; 18(3):80-8. PubMed ID: 2165997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanisms for the development of quinolone resistance].
    Kojima M
    Nihon Rinsho; 1997 May; 55(5):1252-60. PubMed ID: 9155183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of fluoroquinolones against gram-positive bacteria.
    Bush K; Goldschmidt R
    Curr Opin Investig Drugs; 2000 Sep; 1(1):22-30. PubMed ID: 11249591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinolone antimicrobial agents: mechanism of action and resistance development.
    Bryan LE; Bedard J; Wong S; Chamberland S
    Clin Invest Med; 1989 Feb; 12(1):14-9. PubMed ID: 2537696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of Bay y3118 against quinolone-susceptible and -resistant gram-negative and gram-positive bacteria.
    Piddock LJ; Marshall AJ; Jin YF
    Antimicrob Agents Chemother; 1994 Mar; 38(3):422-7. PubMed ID: 8203834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
    Pong A; Thomson KS; Moland ES; Chartrand SA; Sanders CC
    J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones.
    Alexandrakis G; Alfonso EC; Miller D
    Ophthalmology; 2000 Aug; 107(8):1497-502. PubMed ID: 10919897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the mechanism of action and resistance of two new fluoroquinolones, rufloxacin and MF961 with those of ofloxacin and fleroxacin in gram-negative and gram-positive bacteria.
    Piddock LJ; Panchal S; Norte V
    J Antimicrob Chemother; 1993 Jun; 31(6):855-63. PubMed ID: 8395493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quinolone resistance by mutations in chromosomal gyrase genes. Just the tip of the iceberg?
    Martínez JL; Alonso A; Gómez-Gómez JM; Baquero F
    J Antimicrob Chemother; 1998 Dec; 42(6):683-8. PubMed ID: 10052889
    [No Abstract]   [Full Text] [Related]  

  • 12. Mechanisms of quinolone resistance in clinical isolates: accumulation of sparfloxacin and of fluoroquinolones of various hydrophobicity, and analysis of membrane composition.
    Denis A; Moreau NJ
    J Antimicrob Chemother; 1993 Sep; 32(3):379-92. PubMed ID: 8262860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
    Fisher LM; Lawrence JM; Josty IC; Hopewell R; Margerrison EE; Cullen ME
    Am J Med; 1989 Nov; 87(5A):2S-8S. PubMed ID: 2574005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impermeability to quinolones in gram-positive and gram-negative bacteria.
    Bryan LE; Bedard J
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):232-9. PubMed ID: 1864283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of action and resistance of older and newer fluoroquinolones.
    Hooper DC
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S24-8. PubMed ID: 10984324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis.
    Tankovic J; Bachoual R; Ouabdesselam S; Boudjadja A; Soussy CJ
    J Antimicrob Chemother; 1999 May; 43 Suppl B():19-23. PubMed ID: 10382871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.
    Oh H; El Amin N; Davies T; Appelbaum PC; Edlund C
    Antimicrob Agents Chemother; 2001 Jul; 45(7):1977-81. PubMed ID: 11408211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA gyrase-mediated natural resistance to fluoroquinolones in Ehrlichia spp.
    Maurin M; Abergel C; Raoult D
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2098-105. PubMed ID: 11408229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.